Makes insulin syringes and pen needles for diabetes management.
Jun 2026Revenue $1.02B/yrExpenses $795M/yr
No trend
Figures by year
Is Embecta profitable?
Yes. In the 12 months to Jun 2026, revenue was $1.02B and expenses $795M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $1.08B | $838M | $242M |
| Sep 2024 | $1.12B | $956M | $167M |
| Sep 2023 | $1.12B | $899M | $222M |
| Sep 2022 | $1.13B | $820M | $310M |
| Sep 2021 | $1.17B | $673M | $492M |
| Sep 2020 | $1.09B | $599M | $487M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.